|Application ||IHC, IF, FC|
|Isotype||Mouse / IgM, kappa|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Nord�n R et al. Glycobiology 23:310-21 (2013)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.